Market Cap 11.40B
Revenue (ttm) 705.14M
Net Income (ttm) -453.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -64.37%
Debt to Equity Ratio 0.09
Volume 1,990,300
Avg Vol 2,556,316
Day's Range N/A - N/A
Shares Out 159.39M
Stochastic %K 18%
Beta 0.33
Analysts Strong Sell
Price Target $76.09

Company Profile

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treat...

Industry: Biotechnology
Sector: Healthcare
Phone: 760 931 9200
Address:
2855 Gazelle Court, Carlsbad, United States
BioRich
BioRich Oct. 25 at 5:10 AM
$ALT Thanks to Mr. 32K Shares for trying to pump $SNY as hopeful suitor showing pity on the dying quail, ALT. It motivated to use this boards favorite tool (AI) and ask: "If Sanofi were to buy a MASH company, who would they buy?" Answer: 1) $MDGL 2) $IVA 3) $IONS My pick is $IVA. I think a deal is done and they are just waiting for the ink to dry. Sorry ALT Nation, no mention of $ALT. Not for buyout. Not for partnership. Not for licensing. ChatGPT didn't even acknowledge $ALT was a player when it listed off other potential candidates.
0 · Reply
Anastasia99
Anastasia99 Oct. 25 at 1:10 AM
0 · Reply
JFDI
JFDI Oct. 24 at 8:14 PM
0 · Reply
Gaox01
Gaox01 Oct. 24 at 11:45 AM
$IONS Ionis Ionis has been named #2 employer by Science magazine 2025. https://ir.ionis.com/news-releases/news-release-details/ionis-ranked-2-top-employer-science-magazine-recognizing#:~:text=Release%20Details-,Ionis%20ranked%20%232%20Top%20Employer%20by%20Science%20magazine%2C%20recognizing%20industry,scientific%20innovation%20and%20company%20culture
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 17 at 1:19 PM
Enter: $IONS NOV 21 2025 $72 CALLS Buy in Price: $4.40 - $6.20 Take Profit: $9.72 Stop Bleeding: $3.87 ROI Potential: 121% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
JarvisFlow
JarvisFlow Oct. 16 at 5:58 PM
Morgan Stanley has updated their rating for Ionis Pharmaceuticals ( $IONS ) to Overweight with a price target of 90.
0 · Reply
Thenextgme
Thenextgme Oct. 9 at 3:58 PM
$IONS posts like this tell me people lack experience. They will buy the stock at 20$ thinking there is still value. We will read about them in the newspaper, lost all their money committed suicide
1 · Reply
RoyalPurp
RoyalPurp Oct. 8 at 11:05 PM
$IONS She’s moving
0 · Reply
ZorTrades
ZorTrades Oct. 8 at 6:53 PM
Barron’s out cautious on $RGTI $QBTS $IONS $QUBT —- I wonder if the Eiffel tower pattern was part of their analysis.😭 ($IONZ, $QBTZ)
0 · Reply
JarvisFlow
JarvisFlow Oct. 8 at 4:24 PM
Needham updates rating for Ionis Pharmaceuticals ( $IONS ) to Buy, target set at 70 → 78.
0 · Reply
Latest News on IONS
Ionis to hold third quarter 2025 financial results webcast

Oct 16, 2025, 7:05 AM EDT - 9 days ago

Ionis to hold third quarter 2025 financial results webcast


Ionis' brain disorder drug shows promise in clinical trial

Sep 22, 2025, 7:10 AM EDT - 4 weeks ago

Ionis' brain disorder drug shows promise in clinical trial


Ionis to host investors and analysts for Innovation Day 2025

Sep 8, 2025, 4:00 PM EDT - 6 weeks ago

Ionis to host investors and analysts for Innovation Day 2025


Is The 35% Rally In IONS Stock Just The Beginning?

Sep 3, 2025, 10:41 AM EDT - 7 weeks ago

Is The 35% Rally In IONS Stock Just The Beginning?


Ionis to present at upcoming investor conferences

Sep 2, 2025, 4:00 PM EDT - 7 weeks ago

Ionis to present at upcoming investor conferences


mRNA Biotechs - Long-Term Value Risks Abound

Aug 28, 2025, 6:20 AM EDT - 2 months ago

mRNA Biotechs - Long-Term Value Risks Abound

ALNY BNTX DHR GRAL ILMN MRNA RGEN


US FDA approves Ionis' drug for rare genetic disorder

Aug 21, 2025, 11:58 AM EDT - 2 months ago

US FDA approves Ionis' drug for rare genetic disorder


Ionis to hold second quarter 2025 financial results webcast

Jul 16, 2025, 7:05 AM EDT - 3 months ago

Ionis to hold second quarter 2025 financial results webcast


Ionis to host 2025 virtual Annual Meeting of Stockholders

May 6, 2025, 7:05 AM EDT - 6 months ago

Ionis to host 2025 virtual Annual Meeting of Stockholders


Ionis reports first quarter 2025 financial results

Apr 30, 2025, 7:00 AM EDT - 6 months ago

Ionis reports first quarter 2025 financial results


Ionis to host expert panel discussion on sHTG

Apr 3, 2025, 7:05 AM EDT - 7 months ago

Ionis to host expert panel discussion on sHTG


BioRich
BioRich Oct. 25 at 5:10 AM
$ALT Thanks to Mr. 32K Shares for trying to pump $SNY as hopeful suitor showing pity on the dying quail, ALT. It motivated to use this boards favorite tool (AI) and ask: "If Sanofi were to buy a MASH company, who would they buy?" Answer: 1) $MDGL 2) $IVA 3) $IONS My pick is $IVA. I think a deal is done and they are just waiting for the ink to dry. Sorry ALT Nation, no mention of $ALT. Not for buyout. Not for partnership. Not for licensing. ChatGPT didn't even acknowledge $ALT was a player when it listed off other potential candidates.
0 · Reply
Anastasia99
Anastasia99 Oct. 25 at 1:10 AM
0 · Reply
JFDI
JFDI Oct. 24 at 8:14 PM
0 · Reply
Gaox01
Gaox01 Oct. 24 at 11:45 AM
$IONS Ionis Ionis has been named #2 employer by Science magazine 2025. https://ir.ionis.com/news-releases/news-release-details/ionis-ranked-2-top-employer-science-magazine-recognizing#:~:text=Release%20Details-,Ionis%20ranked%20%232%20Top%20Employer%20by%20Science%20magazine%2C%20recognizing%20industry,scientific%20innovation%20and%20company%20culture
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 17 at 1:19 PM
Enter: $IONS NOV 21 2025 $72 CALLS Buy in Price: $4.40 - $6.20 Take Profit: $9.72 Stop Bleeding: $3.87 ROI Potential: 121% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
JarvisFlow
JarvisFlow Oct. 16 at 5:58 PM
Morgan Stanley has updated their rating for Ionis Pharmaceuticals ( $IONS ) to Overweight with a price target of 90.
0 · Reply
Thenextgme
Thenextgme Oct. 9 at 3:58 PM
$IONS posts like this tell me people lack experience. They will buy the stock at 20$ thinking there is still value. We will read about them in the newspaper, lost all their money committed suicide
1 · Reply
RoyalPurp
RoyalPurp Oct. 8 at 11:05 PM
$IONS She’s moving
0 · Reply
ZorTrades
ZorTrades Oct. 8 at 6:53 PM
Barron’s out cautious on $RGTI $QBTS $IONS $QUBT —- I wonder if the Eiffel tower pattern was part of their analysis.😭 ($IONZ, $QBTZ)
0 · Reply
JarvisFlow
JarvisFlow Oct. 8 at 4:24 PM
Needham updates rating for Ionis Pharmaceuticals ( $IONS ) to Buy, target set at 70 → 78.
0 · Reply
JarvisFlow
JarvisFlow Oct. 8 at 3:51 PM
Oppenheimer has updated their rating for Ionis Pharmaceuticals ( $IONS ) to Outperform with a price target of 90.
0 · Reply
briefingcom
briefingcom Oct. 8 at 12:47 PM
$IONS: Ionis Pharma upgraded to Overweight from Neutral at JP Morgan, tgt $80 View More Stock Upgrades: https://www.briefing.com/calendars/updown?Filter=upgrades&utm_campaign=updown&utm_medium=social&utm_source=st&utm_content=link
0 · Reply
notreload_ai
notreload_ai Oct. 8 at 12:20 PM
JPMorgan analyst upgrades $IONS to Overweight, raising price target to $80 from $49, citing strong drug launches and path to profitability. https://notreload.xyz/jpmorgan-boosts-ionis-stock-rating-strong-drug-pipeline/
0 · Reply
ChessGM
ChessGM Oct. 8 at 12:10 PM
$IONS JP Morgan Upgrades Ionis Pharmaceuticals to Overweight, Raises Price Target to $80
0 · Reply
Quantumup
Quantumup Oct. 8 at 11:48 AM
H.C. Wainwright reiterated $ARWR Buy-$80/said, With the November 18 PDUFA action date for plozasiran in familial chylomicronemia syndrome (FCS) approaching, we conducted several calls with Arrowhead management and key opinion leaders (KOLs) in the space. $IONS H.C. Wainwright added:
0 · Reply
JarvisFlow
JarvisFlow Oct. 8 at 10:18 AM
HC Wainwright & Co. updates rating for Ionis Pharmaceuticals ( $IONS ) to Buy, target set at 95.
0 · Reply
johnnygogogo
johnnygogogo Oct. 7 at 5:59 PM
$IONS wonder which bank got the CEO booked on CNBC / Squawk Box (it wasn’t their own PR department, I’ll tell you that much). Best guess is Goldman or Morgan Scamley and it has to do with pumping the convertible debt. (“For its June 2023 convertible senior notes offering, Ionis Pharmaceuticals worked with multiple "initial purchasers," including affiliates of Morgan Stanley and Goldman Sachs. The law firm Cooley LLP advised Ionis on the offering. “) cc @skeezbag
1 · Reply
itsmetradingstocks
itsmetradingstocks Oct. 7 at 3:57 PM
$IONS 2028 CF positive
1 · Reply
Im_a_realist
Im_a_realist Oct. 7 at 11:34 AM
$IONS CEO says "we'll make money or we won't make money" when asked if he has concerns about going after rare diseases. WTF kinda answer is that? So much for share holders long term.
1 · Reply
JarvisFlow
JarvisFlow Oct. 6 at 12:24 PM
Stifel updates rating for Ionis Pharmaceuticals ( $IONS ) to Hold, target set at 43 → 67.
0 · Reply
FloatFrenzy
FloatFrenzy Oct. 5 at 8:01 AM
$IONS Biopharmaceutical focus. Trading near cash value. High short interest. Binary event risk on data.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 4 at 1:10 AM
Enter: $IONS NOV 21 2025 $68 CALLS Buy in Price: $3.95 - $5.60 Take Profit: $7.43 Stop Bleeding: $3.48 ROI Potential: 88% Exit Within: 174 Minutes https://moneygroup.us/alerts
0 · Reply